Abstracts

To evaluate the efficacy and safety of topiramate used as monotherapy in adult patients with recently diagnosed partial-onset seizures. A 6-month, open-label, uncontrolled trial was undertaken in 28 patients. Eligible patients were aged [underline][gt][/underline] 16 years and weight [underline][gt][/underline] 30 kg with the maximum interval since epilepsy diagnosis was 3 years and had at least one partial-onset seizure during a 3-months retrospective baseline phase. The main outcome measures proportion of patients who showed 50% or greater reduction in frequency of seizures and withdraw from the study for any reason. Topiramate was initiated at 50 mg/day and titrated to a recommended dose of 200-400 mg/day Topiramate treated patients demonstrated significant improvement in seizure severity based on 77.3% were seizure-free. The percentage of patients with a [underline][gt][/underline]50% seizure rate reduction from baseline was 13.6%, and 9.1% were not improved. There were no discontinuations from the study due to adverse events. The adverse events were mild intensity included paresthesia, dizziness, weight loss, anorexia, numbness, slow mentation, and hypoesthesia. The study suggests that topiramate in doses 50-200 mg/day was well tolerated and effective in the monotherapy treatment of patients with partial epilepsy. (Supported by Janssen-Cilag ,Tahiland.)